James Loerop Aclaris Therapeutics, Inc. (ACRS) insider trading activity

James Loerop is Chief Business Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 155,041 shares of ACRS, which is worth approximately $390,703. The most recent transaction as insider was on Jan 02, 2026, when has been sold 6,171 shares (Common Stock) at a price of $2.88 per share, resulting in proceeds of $17,772. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 155K

50.08% 3M change

81.86% 12M change

Total Value Held $390,703

James Loerop Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	SELL Payment of exercise price or tax liability	$17,772 $2.88 p/Share	6,171 Reduced 3.83%	155,041 Common Stock
Jan 02 2026	BUY Exercise of conversion of derivative security	-	18,150 Added 10.12%	161,212 Common Stock
Dec 31 2025	SELL Payment of exercise price or tax liability	$102,321 $3.01 p/Share	33,994 Reduced 19.2%	143,062 Common Stock
Dec 31 2025	BUY Exercise of conversion of derivative security	-	73,750 Added 29.41%	177,056 Common Stock
Feb 01 2025	SELL Payment of exercise price or tax liability	$38,308 $2.48 p/Share	15,447 Reduced 13.01%	103,306 Common Stock
Feb 01 2025	BUY Exercise of conversion of derivative security	-	33,500 Added 22.0%	118,753 Common Stock
Jan 02 2025	SELL Payment of exercise price or tax liability	$21,266 $2.48 p/Share	8,575 Reduced 9.14%	85,253 Common Stock

Jan 02 2025	BUY Exercise of conversion of derivative security	-	18,150 Added 16.21%	93,828 Common Stock
Dec 31 2024	SELL Payment of exercise price or tax liability	$79,580 $2.48 p/Share	32,089 Reduced 29.78%	75,678 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	-	73,750 Added 40.63%	107,767 Common Stock
Feb 01 2024	SELL Payment of exercise price or tax liability	$7,705 $1.2 p/Share	6,421 Reduced 15.88%	34,017 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	-	18,750 Added 33.88%	36,585 Common Stock
Aug 28 2023	BUY Open market or private purchase	$99,994 $6.8 p/Share	14,705 Added 40.41%	21,688 Common Stock
Feb 08 2023	SELL Open market or private sale	$59,268 $13.89 p/Share	4,267 Reduced 37.93%	6,983 Common Stock
Feb 01 2023	BUY Exercise of conversion of derivative security	-	11,250 Added 50.0%	11,250 Common Stock

Also insider at

ANIK

Anika Therapeutics, Inc. Healthcare

EVP Business Development

James Loerop

Chief Business Officer

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account